DOCSLIB.ORG

Vaccinate Adults May 2015

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccinate Adults May 2015 Volume 19 – Number 2 May 2015 (Content current VACCINATE ADULTS! as of May 26) from the Immunization Action Coalition — www.immunize.org New ACIP recommendations for HPV, influenza, What’s In This Issue MenB, typhoid, and yellow fever vaccines. Make New ACIP Recommendations ..............................1 sure you’re up to date! Ask the Experts: CDC Answers Your Questions ..............................1 An abundance of new guidance has recently been girls at age 11 or 12 years, with HPV vaccine use IAC’s Redesigned issued for the use of vaccines by the Centers for recommended for females through age 26 and for “Talking About Vaccines” Web Section .................2 Disease Control and Prevention’s (CDC) Advisory males through age 21, as well as for men through Committee on Immunization Practices (ACIP) age 26 who are immunocompromised or who have Vaccine Highlights ................................................4 in 2015 and more will be published soon. The gui- sex with men. For females, the 2-valent (2vHPV, Recommended U.S. Adult dance covers the use of 9-valent human papil- Cervarix, GlaxoSmithKline), 4-valent (4vHPV, Immunization Schedule ......................................16 lomavirus vaccine (9vHPV, Gardasil 9, Merck); Gardasil, Merck), or 9-valent (9vHPV) HPV meningococcal serotype B vaccines (MenB: vaccines may be used. For males, either 4vHPV Guide to Contraindications and Precautions Bexsero, GlaxoSmithKline; Trumenba, Pfizer); or 9vHPV should be administered. Any recom- to Commonly Used Vaccines in Adults .................9 influenza vaccines, typhoid vaccines (Typhim Vi, mended HPV vaccine, including 9vHPV, may be Vaccination Schedules for All Adults Sanofi Pasteur; Vivotif, PaxVax) and yellow fever used to complete a previously begun HPV vaccine and High-risk Adults ............................................10 vaccine (YF, YF-VAX, Sanofi-Pasteur). series. Updated ACIP HPV recommendations are The following provides a brief summary of the available online at www.cdc.gov/mmwr/pdf/wk/ Vaccinations for Pregnant Women ..................... 11 recent changes voted upon at the February ACIP meet- mm6411.pdf, pages 300–304. Patient Handout: Protect Yourself from ing, as well as recommendations recently published Pneumococcal Disease...Get Vaccinated! ..........12 in Morbidity and Mortality Weekly Report (MMWR). Influenza vaccine Medical Management of Vaccine Reactions Human papillomavirus vaccine At its February meeting, ACIP voted to approve in Adults ..............................................................13 its annual influenza vaccine recommendations for On March 27, MMWR published “Use of 9-Valent the 2015–2016 influenza season. The committee Handy VIS Reference Charts .............................14 Human Papillomavirus (HPV) Vaccine: Updated reaffirmed the need for annual influenza vac- The Vaccine Handbook: HPV Vaccination Recommendations of the ACIP.” cination for all people age 6 months and older. A Practical Guide for Clinicians ..........................15 The new 9vHPV vaccine is recommended for Access a related CDC press release at www.cdc. use along with the other HPV vaccines already gov/media/releases/2015/s0226-acip.html. IAC’s Immunization Resources Order Form .......18 recommended for use by ACIP. The recommen- dations include HPV vaccination of all boys and Recommendations...continued on page 5 Are healthcare personnel at risk of occupa- HPV vaccine tional infection with HPV? Ask the Occupational infection with HPV is possible. Which types of HPV are most likely Some HPV-associated conditions (including ano- to cause disease? genital and oral warts, anogenital intraepithelial Experts Of the annual average of 26,900 HPV-related can- neoplasias, and recurrent respiratory papilloma- The Immunization Action Coalition extends thanks cers in the United States, approximately 64% are tosis) are treated with laser or electrosurgical to our experts, medical officer Andrew T. Kroger, attributable to HPV 16 or 18 (65% for females; 63% procedures that could produce airborne particles. MD, MPH, and nurse educator Donna L. Weaver, for males; approximately 21,300 cases annually), These procedures should be performed in an RN, MN, both with the National Center for Immu- which are included in all three HPV vaccines. Ap- appropriately ventilated room using standard nization and Respiratory Diseases at the Centers proximately 10% are attributable to HPV types 31, precautions and local exhaust ventilation. Workers for Disease Control and Prevention (CDC). 33, 45, 52, and 58 (14% for females; 4% for males; in HPV research laboratories who handle wild- approximately 3,400 cases annually), which are type virus or “quasi virions” might be at risk of included in the 9-valent HPV vaccine. HPV type acquiring HPV from occupational exposures. In Stay current with FREE subscriptions 16, 18, 31, 33, 45, 52, or 58 account for about 81% The Immunization Action Coalition’s of cervical cancers in the United States. Ask the Experts...continued on page 22 2 periodicals, Vaccinate Adults and Approximately 50% of cervical precancers Needle Tips, and our email news (CIN2 or greater) are caused by HPV 16 or 18 and service, IAC Express, are packed 25% by HPV 31, 33, 45, 52, or 58. HPV 6 or 11 Immunization questions? with up-to-date information. cause 90% of anogenital warts (condylomata) and Email [email protected] Subscribe to all 3 free publications in most cases of recurrent respiratory papillomatosis. Call your state health department one place. It’s simple! Go to More information about HPV and HPV-related (phone numbers at cancers is available in the 2014 HPV ACIP state- www.immunize.org/subscribe www.immunize.org/coordinators) ment at www.cdc.gov/mmwr/pdf/rr/rr6305.pdf. Recommendations...continued from page 1 No preference was stated on the use of one MenB Typhi (i.e., microbiologists/laboratory workers and vaccine over the other. intimate contacts of documented chronic carriers). Meningococcal B vaccine ACIP delayed its discussion about the use of MenB vaccine in adolescents and college students Yellow fever vaccine Also in February, ACIP voted that a series of either until the June meeting. of the recently licensed MenB vaccines should ACIP voted to recommend that a single dose of be administered to people 10 years of age and Typhoid vaccine yellow fever (YF) vaccine provides long-lasting older who are at increased risk of meningococcal protection and is adequate for most travelers. disease. These individuals include: On March 27, CDC published “Updated Recom- ACIP also stated that additional doses of YF • People with persistent complement component mendations for the Use of Typhoid Vaccine – ACIP, vaccine may be indicated for certain populations. deficiencies, including inherited or chronic U.S., 2015” in MMWR (www.cdc.gov/mmwr/pdf/ A booster dose of YF vaccine may be considered deficiencies in C3, C5-9, properdin, factor D, wk/mm6411.pdf, pages 305–308). for travelers who received their last dose at least factor H, or taking eculizumab; These revised ACIP recommendations include 10 years previously and who will be in a higher- • People with anatomic or functional asplenia, updated information on the two currently available risk setting based on season, location, activities, including sickle cell disease; typhoid vaccines and on vaccine safety. Routine and duration of their travel. For more details, see • Microbiologists routinely exposed to isolates of typhoid vaccination is not recommended in the IAC’s ACIP meeting summary in “Technically Neisseria meningitidis; and U.S. The vaccine is recommended for international Speaking,” April 2015, www.immunize.org/ • People identified to be at increased risk because travelers to specific areas, as well as for those technically-speaking/20150401.asp. of a meningococcal B outbreak. who are routinely exposed to Salmonella serotype Apply for IAC’s Influenza Vaccination Honor Roll Join more than 500 healthcare Laminated U.S. settings already honored! Immunization Schedules Purchase IAC’s laminated versions of the 2015 U.S. immunization schedules for children (0–18 years old) and This honor roll recognizes health- adults. Both are laminated care settings that have implemented and washable for heavy-duty mandatory vaccination policies for use, complete with essential healthcare personnel (HCP). footnotes, and printed in To find the healthcare settings listed color for easy reading. by state, visit www.immunize.org/ honor-roll/influenza-mandates/ honorees.asp More information and discount pricing options are available online To read position statements sup- at www.immunize.org/laminated- porting mandatory HCP vaccination schedules or see the order form from leading healthcare organizations on page 24. and professional medical societies or to apply, visit www.immunize.org/ honor-roll/influenza-mandates Vaccinate Adults! • May 2015 • Immunization Action Coalition • (651) 647-9009 • www.immunize.org • www.vaccineinformation.org 5.
Load more

Recommended publications
  • Yellow Fever Vaccine See Hojas De Información Sobre Vacunas Están Disponibles En Español Y En Muchos Otros What You Need to Know Idiomas
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. Yellow Fever Vaccine See www.immunize.org/vis Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis 1 What is yellow fever? 3 Yellow fever vaccine Yellow fever is a serious disease caused by the yellow Yellow fever vaccine is a live, weakened virus. It is fever virus. It is found in certain parts of Africa and given as a single shot. For people who remain at risk, a South America. booster dose is recommended every 10 years. Yellow fever is spread through the bite of an infected Yellow fever vaccine may be given at the same time as mosquito. It cannot be spread person to person by direct most other vaccines. contact. Who should get yellow fever vaccine? People with yellow fever disease usually have to be • Persons 9 months through 59 years of age traveling hospitalized. Yellow fever can cause: to or living in an area where risk of yellow fever is • fever and flu-like symptoms known to exist, or traveling to a country with an entry • jaundice (yellow skin or eyes) requirement for the vaccination. • bleeding from multiple body sites • Laboratory personnel who might be exposed to yellow • liver, kidney, respiratory and other organ failure fever virus or vaccine virus. • death (20% - 50% of serious cases) Information for travelers can be found online through CDC (www.cdc.gov/travel), the World Health 2 How can I prevent yellow fever? Organization (www.who.int), and the Pan American Health Organization (www.paho.org).
    [Show full text]
  • Recombivax HB , YF-Vax – Drug Shortages
    Recombivax HB®, YF-Vax® – Drug shortages • The drug shortages of Recombivax HB (hepatitis B vaccine, recombinant) and YF-Vax (yellow fever virus strain 17d-204 live antigen) are ongoing. Recombivax HB and YF-Vax have been unavailable for at least 90 days. Product Description NDC # Recombivax HB (hepatitis B vaccine, recombinant) 0.5 mL (5 mcg) 0006-4981-00, 0006- pediatric/adolescent formulation 4093-02, 0006-4093-09 single-dose vials and prefilled syringes Recombivax HB (hepatitis B vaccine, 0006-4995-00, 0006- recombinant) 1 mL (10 mcg) adult 4995-41, 0006-4094-02, formulation single-dose vials and 0006-4094-09 prefilled syringes YF-Vax (yellow fever virus strain 17-d- 49281-0915-01, 49281- 2014 live antigen) single- and multi- 0915-05 dose vials — The shortage of Recombivax HB is due to increased global demand. — The Recombivax HB pediatric/adolescent and adult formulations are estimated to be available in the first half of 2018 and the first half of 2019, respectively. — The Recombivax HB dialysis formulation is available; however, the dose is different than the adult and pediatric/adolescent formulations. — YF-Vax is unavailable because the manufacturer, Sanofi Pasteur, is transitioning production to a new facility in 2018. YF-Vax is estimated to be available by mid-2018. • Recombivax HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. — Engerix-B™ (hepatitis B vaccine, recombinant) is another currently available vaccine that carries the same indication as Recombivax HB. Engerix-B is not in shortage. — Heplisav-B™ (hepatitis B vaccine, recombinant) was recently approved and carries the same indication as Recombivax HB.
    [Show full text]
  • Yellow Fever Vaccine Program Manual
    Vaccine Preventable Disease Program Yellow Fever Vaccine Program Manual New Jersey Department of Health Vaccine Preventable Disease Program P.O. Box 369 Trenton, NJ 08625 Phone 609-826-4860 Table of Contents Yellow Fever Certification ......................................................... 1 Certified Uniform Yellow Fever Stamp Holder .......................... 1 Certified Yellow Fever Vaccine Uniform Stamp ........................ 1 Who Can Apply? ...................................................................... 2 Application Requirements ........................................................ 2 Responsibilities of Uniform Stamp Holder ................................ 3 Period of Certification/Recertification ........................................ 4 Responsibilities of Yellow Fever Vaccine Coordinator .............. 4 Registries ................................................................................. 4 Change Notifications ................................................................ 5 Replacement Stamp ................................................................. 5 Standards, Recordkeeping, and Storage .................................. 5 YEL LOW FEVER VACCINE PR OGRAM Yellow Fever Certification According to International Health Regulations, yellow fever vaccine must be administered at certified yellow fever vaccination centers. Healthcare providers are authorized to administer the vaccine by state health departments and the states then report certified providers to the Centers for Disease Control and Prevention
    [Show full text]
  • Yellow Fever Vaccine
    Yellow Fever Vaccine: Current Supply Outlook UNICEF Supply Division May 2016 0 Yellow Fever Vaccine - Current Supply Outlook May 2016 This update provides revised information on yellow fever vaccine supply availability and increased demand. Despite slight improvements in availability and the return of two manufacturers from temporary suspension, a constrained yellow fever vaccine market will persist through 2017, exacerbated by current emergency outbreak response requirements. 1. Summary Yellow fever vaccine (YFV) supply through UNICEF remains constrained due to limited production capacity. Despite the return of two manufacturers from temporary suspension, the high demand currently generated from the yellow fever (YF) outbreak in Angola, in addition to potential increased outbreak response requirements in other geographic regions, outweigh supply. The demand in response to the current YF outbreak in Angola could negatively impact the supply availability for some routine immunization programme activities. UNICEF anticipates a constrained global production capacity to persist through 2017. UNICEF has long-term arrangements (LTAs) with four YFV suppliers to cover emergency stockpile, routine immunization, and preventative campaign requirements. During 2015, UNICEF increased total aggregate awards to suppliers to reach approximately 98 million doses for 2016- 2017. However, whereas supply can meet emergency stockpile and routine requirements, it is insufficient to meet all preventive campaign demands, which increased the total demand through UNICEF to 109 million doses. The weighted average price (WAP) per dose for YFV increased 7% a year on average since 2001, from US$ 0.39 to reach US$ 1.04 in 2015. Given the continued supply constraints, UNICEF anticipates a YFV WAP per dose of US$1.10 in the near-term.
    [Show full text]
  • Typhoid Vaccine W H a T Y O U N E E D T O K N O W
    TYPHOID VACCINE W H A T Y O U N E E D T O K N O W Many Vaccine Information Statements are available in Spanish and other languages. See www.immunize.org/vis. What is typhoid? •Travelers to parts of the world where typhoid is 1 common. (NOTE: typhoid vaccine is not 100% Typhoid (typhoid fever) is a serious disease. It is effective and is not a substitute for being caused by bacteria called Salmonella Typhi. careful about what you eat or drink.) Typhoid causes a high fever, weakness, stomach •People in close contact with a typhoid carrier. pains, headache, loss of appetite, and sometimes a •Laboratory workers who work with Salmonella rash. If it is not treated, it can kill up to 30% of Typhi bacteria. people who get it. Some people who get typhoid become “carriers,” Inactivated Typhoid Vaccine (Shot) who can spread the •Should not be given to children younger than 2 disease to years of age. others. •One dose provides protection. It should be given Generally, at least 2 weeks before travel to allow the vaccine people get time to work. typhoid from contaminated •A booster dose is needed every 2 years for people food or water. Typhoid is not common in the U.S., who remain at risk. and most U.S. citizens who get the disease get it Live Typhoid Vaccine (Oral) while traveling. Typhoid strikes about 21 million people a year around the world and kills about •Should not be given to children younger than 6 200,000. years of age.
    [Show full text]
  • Vaccine Adjuvants Derived from Marine Organisms
    biomolecules Review Vaccine Adjuvants Derived from Marine Organisms Nina Sanina Department of Biochemistry, Microbiology and Biotechnology, School of Natural Sciences, Far Eastern, Federal University, Sukhanov Str., 8, Vladivostok 690091, Russia; [email protected]; Tel.: +7-423-265-2429 Received: 10 July 2019; Accepted: 1 August 2019; Published: 3 August 2019 Abstract: Vaccine adjuvants help to enhance the immunogenicity of weak antigens. The adjuvant effect of certain substances was noted long ago (the 40s of the last century), and since then a large number of adjuvants belonging to different groups of chemicals have been studied. This review presents research data on the nonspecific action of substances originated from marine organisms, their derivatives and complexes, united by the name ‘adjuvants’. There are covered the mechanisms of their action, safety, as well as the practical use of adjuvants derived from marine hydrobionts in medical immunology and veterinary medicine to create modern vaccines that should be non-toxic and efficient. The present review is intended to briefly describe some important achievements in the use of marine resources to solve this important problem. Keywords: squalene; cucumariosides; chitosan; fucoidans; carrageenans; laminarin; alginate 1. Introduction The oil-in-water-based complete Freund’s adjuvant developed by Jules Freund and Katherine McDermott in 40s of last century is the first vaccine adjuvant. The basis of immune stimulation and provide immunologists with a way to stimulate the production of antibodies and cellular immune responses to weak antigens. This elaboration allowed to establish the basis of immune stimulation and provide immunologists with an instrument to stimulate the production of antibody and cellular immune responses to weak antigens.
    [Show full text]
  • 2021 Medicare Vaccine Coverage Part B Vs Part D
    CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac­ • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert,
    [Show full text]
  • Optimizing Vaccine Allocation for COVID-19 Vaccines Shows The
    ARTICLE https://doi.org/10.1038/s41467-021-23761-1 OPEN Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination ✉ Laura Matrajt 1 , Julia Eaton 2, Tiffany Leung 1, Dobromir Dimitrov1,3, Joshua T. Schiffer1,4,5, David A. Swan1 & Holly Janes1 1234567890():,; Most COVID-19 vaccines require two doses, however with limited vaccine supply, policy- makers are considering single-dose vaccination as an alternative strategy. Using a mathe- matical model combined with optimization algorithms, we determined optimal allocation strategies with one and two doses of vaccine under various degrees of viral transmission. Under low transmission, we show that the optimal allocation of vaccine vitally depends on the single-dose efficacy. With high single-dose efficacy, single-dose vaccination is optimal, preventing up to 22% more deaths than a strategy prioritizing two-dose vaccination for older adults. With low or moderate single-dose efficacy, mixed vaccination campaigns with com- plete coverage of older adults are optimal. However, with modest or high transmission, vaccinating older adults first with two doses is best, preventing up to 41% more deaths than a single-dose vaccination given across all adult populations. Our work suggests that it is imperative to determine the efficacy and durability of single-dose vaccines, as mixed or single-dose vaccination campaigns may have the potential to contain the pandemic much more quickly. 1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2 School of Interdisciplinary Arts and Sciences, University of Washington, Tacoma, WA, USA. 3 Department of Applied Mathematics, University of Washington, Seattle, WA, USA.
    [Show full text]
  • The Present and Future of Yellow Fever Vaccines
    pharmaceuticals Review The Present and Future of Yellow Fever Vaccines Clairissa A. Hansen 1 and Alan D. T. Barrett 1,2,* 1 Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA; [email protected] 2 Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555-4036, USA * Correspondence: [email protected] Abstract: The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non- human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing.
    [Show full text]
  • Oklahoma State Department of Health 01-2018 Revised Immunization
    Oklahoma State Department of Health 01-2018 Revised IMMUNIZATION I. DEFINITION: The process whereby a person is made immune or resistant to an infectious disease. This term is often used interchangeably with vaccination or inoculation. II. CLINICAL FEATURES: (ACTIVE IMMUNITY) Results when exposure to a disease organism triggers the immune system to produce antibodies to that disease. Exposure to the disease organism can occur through infection with the actual disease (resulting in natural immunity), or introduction of a killed or weakened form of the disease organism through vaccination (vaccine-induced immunity). Active immunity is long-lasting, and sometimes life-long. III. MANAGEMENT PLAN: A. Administer immunizations provided by the health department per the most current recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease and Control (CDC). B. The PHN is to administer all immunizations due at the visit. If this does not occur, the PHN is to document the reason in the client record. The parent is to be educated on the safety concerns and issues raised by not immunizing their child as recommended. C. For Mass Clinic Administration: Do NOT prefill syringes or pre-open syringes/needles. This compromises sterility and vaccine competency. D. Immunization for International Travelers: Information concerning the specific recommendations and requirements for immunization of international travelers can be found in the Centers for Disease Control and Prevention (CDC) publication Health Information for International Travel, the “Yellow Book”. This publication may be accessed online at http://www.cdc.gov/travel/yb/index.htm. For the most current information, travelers may be referred to CDC’s website at www.cdc.gov/travel.
    [Show full text]
  • Routine Immunizations
    Drug and Biologic Coverage Policy Effective Date ............................................... 7/1/2021 Next Review Date ......................................... 4/1/2022 Coverage Policy Number .................................. 9001 Routine Immunizations Table of Contents Related Coverage Resources Coverage Policy ................................................... 1 Preventive Care Services General Background ............................................ 2 Covid-19 Vaccine Coding/Billing Information .................................... 3 References .......................................................... 7 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event
    [Show full text]
  • Integration of Typhoid Conjugate Vaccine in National Immunization Schedules: Opportunities and Challenges
    Integration of typhoid conjugate vaccine in national immunization schedules: Opportunities and Challenges. Integration of typhoid9th conjugateInternational vaccine Conferencein national immunization on Typhoid schedules: and Opportunities and invasiveChallenges. NTS Disease 30/04 – 3/05, 2015. Nusa Dua, Bali Objective Review the existing clinical data on Vi conjugate vaccines, based on literature and our experience with Typbar-TCV to ascertain data sufficiency to assist global policy formualtion. Presentation Outline • Need for typhoid vaccine – Disease burden • Typhoid conjugate vaccines – Key considerations • Available data from typhoid conjugate vaccines (TCV) • Programmatic considerations • Integration of TCV into childhood immunization programs Typhoid epidemiology Disease Burden This disease is endemic in most developing countries. Cases/100,00 persons Highly Endemic >100 Endemic 10-100 Sporadic <10 21 million cases worldwide, mortality estimates of 216,000 to 600,000. http://www.who.int/immunization/topics/en/ http://www3.chu-rouen.fr/Internet/services/sante_voyages/pathologies/typhoide/ Age stratified disease burden 0.4 0.3 0.2 0.1 0 Proportion of Cases of Proportion Age groups Crump JA, et al. Bull World Health Organ 2004;82:346-353 Typhoid fever incidence – Asia and Africa • High incidence of typhoid fever in the region. • High incidence in urban slums; rates similar • Substantial regional variation in incidence. to those from Asia. • “Modified” Passive srvlnce. • Lower burden in rural children from Ghana (and Lwak, Kenya), compared to urban Ochiai RL, et al. Bull World Health Organ 2008;86:260-268. Breiman, RF et. al, PLoS One. 2012; 7(1): e29119. areas; regional differences Marks, F et. al, Emerg Infect Dis. 2010; 16(11): 1796–1797.
    [Show full text]